Biological Therapy in Primary Sjogren's Syndrome: Effect on Salivary Gland Function and Inflammation by Chowdhury, F et al.
MINI REVIEW
published: 15 July 2021
doi: 10.3389/fmed.2021.707104
Frontiers in Medicine | www.frontiersin.org 1 July 2021 | Volume 8 | Article 707104
Edited by:
Clio Mavragani,






Juan Carlos Nieto González,





This article was submitted to
Rheumatology,
a section of the journal
Frontiers in Medicine
Received: 08 May 2021
Accepted: 07 June 2021
Published: 15 July 2021
Citation:
Chowdhury F, Tappuni A and
Bombardieri M (2021) Biological
Therapy in Primary Sjögren’s




Biological Therapy in Primary
Sjögren’s Syndrome: Effect on
Salivary Gland Function and
Inflammation
Farzana Chowdhury 1,2, Anwar Tappuni 2 and Michele Bombardieri 1*
1Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, London, United Kingdom,
2 Institute of Dentistry, Barts and the London School of Medicine and Dentistry, London, United Kingdom
Primary Sjögren’s syndrome (pSS) is a chronic, systemic autoimmune disease. It is the
second most common rheumatic autoimmune disorder, affecting 0.7% of European
Americans and up to 1% of people globally. pSS is characterized by the impaired
secretory function of exocrine glands, including salivary and lachrymal glands. A
lymphocytic infiltration of these organs leads to the common and debilitating symptoms
of oral and ocular dryness, majorly affecting the quality of life of these patients. Currently,
no disease-modifying drug has been approved for the treatment of pSS, with therapies
largely aimed at relieving symptoms of dry mouth and dry eyes. In particular, management
of oral dryness still represents a major unmet clinical need in pSS and a significant burden
for patients with this condition. Recently, several randomized clinical trials in pSS with
biological therapies targeting specific mechanistic pathways implicated in the disease
pathogenesis, including B-cell hyperactivity, T-cell co-stimulation and the aberrant role
of cytokines, have been completed with mixed results. In this review, we summarize
evidence from recent clinical trials investigating biological therapy in pSS, specifically
highlighting efficacy, or lack thereof, in modulating local inflammation and improving
salivary gland function.
Keywords: B cell depletion, B/T cell co-stimulation, secretory function, salivary gland histopathology, salivary
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INTRODUCTION
Primary Sjögren’s syndrome (pSS) is described as a systemic autoimmune disease targeting the
exocrine glands, mainly the salivary and lachrymal glands. A focal lymphocytic infiltration around
the intercalated and striated ducts of these organs results in a progressive loss of glandular secretory
function, resulting in debilitating sicca symptoms of xerostomia (dry mouth) and xeropthalmia
(dry eyes), respectively (1). It is well-established that B-cell hyperactivity is a hallmark of the
disease as evidenced by altered circulating levels of B-cells, increase in serum B-cell activating factor
(BAFF); hypergammaglobulinemia; and pSS-associated autoantibodies against ribonucleoproteins
SS-A/Ro and SS-B/La (2). B-cell hyperactivation and local lymphocytic infiltration are also
associated with the development of extraglandular manifestations which occur in a clinically
relevant manner in 30–40% of pSS patients, including articular, renal, pulmonary and peripheral
nervous system involvement (1).
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Whilst the multi-step process leading to salivary gland (SG)
loss of function remains to be established, the enhanced B-cell
autoreactivity is believed to be largely driven by T-B-cell cross-
talk (3). At early disease stages, antigen-presenting cells, but
specifically CD4+ T-cell subsets, predominate inflammatory foci
in the SGs (4), most likely as a result of autoantigen release by
apoptotic and damaged mucosal epithelial cell activation due
to viral insult, although the exact mechanism is not completely
understood (5). The resulting milieu of cytokines and co-
stimulation molecules in the environment activates naïve T-
cells, enabling a secretion of chemokines. These act as the
driving force to recruit other mononuclear lymphoid cells to
the site of inflammation, including B-cells which accumulate in
large numbers at later disease stages (6). In up to a third of
patients, larger foci can develop into organized ectopic lymphoid
structures (ELS), comparable to secondary lymphoid organs
complete with germinal centre (GC)-like function (7).
Despite the progression in understanding pathogenic
mechanisms underlying salivary gland hypofunction in pSS,
current treatment options are focused on relieving symptoms
rather than modifying the course of disease (8). After successful
treatment in other autoimmune diseases like rheumatoid
arthritis (RA), together with advances in the knowledge of pSS
pathogenesis, biological compounds targeting pathways which
mediate B-cell hyperactivity, T-cell co-stimulation and abnormal
pro-inflammatory cytokine release are being investigated
increasingly in clinical trials (Figure 1) (9). Although no
biologics have yet been approved for pSS treatment, results from
open label studies and randomized controlled trials (RCTs) have
been promising (Table 1). In this review, we discuss key clinical
and histological findings, specifically associated with salivary
gland function and inflammation, reported to date from studies
using biological therapy in pSS.
EFFECT OF B-CELL BLOCKADE USING
RITUXIMAB ON SALIVARY GLAND
FUNCTION AND INFLAMMATION
The central role of B-cell hyperactivity in pSS is reflected
in the American College of Rheumatology (ACR)- European
League Against Rheumatism (EULAR) classification criteria,
where the presence of a focal lymphocytic sialadenitis (FLS) in
a labial SG biopsy (whereby a high focus score is frequently
associated with large accumulation of B-cells) or positivity for
circulating anti-SSA/Ro-SSB/La antibodies is mandatory in the
diagnosis of pSS (36). It is of no surprise, therefore, that to
date the most extensively investigated biologic in pSS, rituximab
(RTX), selectively depletes B-cells. The genetically engineered
chimeric IgG1 monoclonal antibody (mAb) is directed against the
transmembrane protein CD20, which mediates B-cell activation,
proliferation and differentiation (37). It is expressed on all
B-cells from the pre-B-cell stage to memory B-cells and is
approved for the treatment of B-cell malignancies (38–41)
and other autoimmune diseases including moderate-to-severe
RA (42). Initial reports of its effectiveness in pSS provided
promising results, however two recent RCTs failed to meet their
primary outcomes. Nevertheless, there is a general consensus
that B-cell depletion in pSS is associated with a significant
improvement (or lack of deterioration) of exocrine function,
salivary output and reduction in inflammatory infiltrates in
the SG.
The first study to test the efficacy of RTX was a single-
centre phase II open label trial consisting of 15 patients.
Following the standard four infusions of 375 mg/m2 RTX
at weekly intervals, stimulated whole salivary flow (SWSF)
improved significantly by the end of the trial at 12 weeks,
in patients who displayed residual glandular function (>0.10
ml/min) at baseline. The study reported subjective oral and
ocular dryness using the EULAR Sjögren’s Syndrome Patient
Reported Index (ESSPRI) which uses visual analogue scales
(VAS). Oral dryness improved by the end of the trial,
suggesting RTX may preserve SG function in at least a subset
of patients with residual glandular activity (10). Subsequent
smaller investigations reported similar improvements in PROs
associated with dryness, together with reductions in parotid
and submandibular SG infiltration, however this was not always
reflected in objective measures of residual glandular function,
measured as unstimulated salivary flow (UWSF) rate (11, 12).
Importantly, RTX appeared less efficacious in trials which
enrolled patients with longer disease durations, as also observed
by stratifying the response in patients with early vs. long-standing
disease (12).
In terms of SG inflammation, an initial study failed to
report any improvement in the SG focus score (FS) (number
of inflammatory foci of 50 cells per 4 mm2 area of tissue)
following two cycles of therapy at 12 weeks, despite a significant
depletion of B-cells in labial SG biopsies and peripheral blood
(12). Sequential repopulation of B-cells was first assessed by Pers
et al., and showed that after B-cell depletion was achieved in SGs
at 16 weeks, this lasted for at least 12 months (13). Alongside a
reduction in CD45+ lymphocyte infiltrating area, B:T-cell ratio
(14) and lympho-epithelial lesion (LEL) development (16), RTX
showed evidence that it may reverse FLS, or the progression
of more advanced infiltrates in the form of ectopic GCs, with
a reduction of their prevalence observed in multiple studies
(14, 16, 17), resulting in partial restoration of SG architecture.
Based on the promising results from open label studies, one
double-blind pilot study and 3 prospective RCTs have followed.
The primary outcome of a 20% improvement in fatigue VAS
score was not met by the pilot study, whilst secondary outcome
measures of UWSF rate and changes in SG manifestations
remained unchanged (18). The first positive RCTwas reported by
Meijer et al., where 30 pSS patients with recent and active disease
were tested with RTX, meeting its primary outcome measure:
a significant improvement in salivary glandular function, as
measured by the SWSF rate. This was reflected in subjective
PROs of sicca symptoms, highlighting clinically meaningful
improvements (15). More limited benefit on SG function was
reported in the TEARs RCT (Tolerance and Efficacy of Rituximab
in Primary Sjogren’s Syndrome, NCT00740948), which failed
to improve 2 out of 4 VASs (based on global disease, pain,
fatigue and dryness) by the end of the 24-week trial. Clinically
significant alleviation in fatigue was achieved rapidly at week 6,
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FIGURE 1 | Demonstration of biological therapies clinically evaluated for the treatment of primary Sjögren’s syndrome (pSS) and their target molecules. B-cell
hyperactivity is a major contributor to pSS pathogenesis, and their numbers can be depleted by anti-CD20 antibody rituximab. B-cells alongside other professional
(macrophages/dendritic cells) and non-professional (epithelial) antigen presenting cells are involved in enhanced T-cell co-stimulation in pSS. Specific co-stimulatory
pathways can be inhibited by abatacept, prezalumab, and iscalimab. Pro-inflammatory effects of cytokine IL-6 can be prevented by tocilizumab therapy, whilst effects
of IFN-γ can be mitigated by inhibition of the JAK/STAT pathway. An additional downstream effect of this is prevention of BAFF expression, which can itself be
targeted by belimumab therapy.
and whilst marked improvements in dryness were observed at
later timepoints in the treatment arm, it was less than the required
30mm improvement using VASs (19). The largest RCT based
in the UK on 133 patients, the Trial of Anti-B-cell Therapy in
patients with primary Sjogren’s Syndrome (TRACTISS), is the
only study to introduce a second course of RTX at 24 weeks
(43), when B-cell repopulation usually occurs (10, 13, 15) and
to prolong therapeutic effects observed at earlier timepoints in
other trials. Although TRACTISS did not achieve its primary
outcome of improvements based on patient-reported VASs (30%
reduction in fatigue or oral dryness) (43), a significant difference
was observed between the placebo and treatment arms when
assessing glandular function (22). A worsening UWSF rate in
the placebo arm was observed whilst RTX maintained glandular
function at weeks 36 and 48 – suggesting block of progression
rather than restoration of exocrine function (43).
Post-hoc analyses on both TEARs and TRACTISS unveiled
promising histological and morphological findings. As the first
study to evaluate the effect of RTX on parotid SG morphology
using ultrasonography, 50% of the TEARs cohort who underwent
this procedure at a single study site significantly improved
their echostructure score (decrease in the number and size
of hypoechoic areas) (20). The same cohort later showed
good correlation with FS (r = 0.61, p < 0.01), suggesting
hypoechoic areas may present inflammatory infiltrates in the
gland (44). Similar analyses on the TRACTISS cohort, this time









































TABLE 1 | Clinical trials which have investigated the effects of biological therapies in pSS.
Therapy References Year Baseline characteristics Effect on SG function SG inflammation














Rituximab Pijpe et al. (10) 2005 Open label 15 2±1 SWSF ↑
UWSF ↔
↓ N/A N/A N/A
Seror et al. (11) 2007 Registry 16 9.5 (0–25) ↔ ↓ N/A N/A N/A
Devauchelle-Pensec et al. (12) 2007 Open label 16 13 ± 10 UWSF ↔ ↓ ↔ B cells ↓ N/A
Pers et al. (13) 2007 Uncontrolled 15 N/A N/A N/A N/A B cells ↓ N/A
Pijpe et al. (14) 2009 Uncontrolled 5 N/A SWSF ↑ N/A N/A CD45+ area ↓
B: T cell ratio
↓ LEL ↓
N/A
Meijer et al. (15) 2010 RCT 30 5 ± 4 SWSF↑
UWSF↑
↓ N/A N/A N/A










Dass et al. (18) 2008 RCT pilot 17 7 (1–18) USWF↔ N/A ↔ N/A
Devauchelle-Pensec et al. (19) 2014 RCT 120 5 ± 5 ↔ ↔ N/A N/A N/A
Jousse-Joulin et al. (20) 2015 N/A N/A N/A N/A Echostructure
score ↓
Cornec et al. (21) 2016 N/A N/A N/A B cells ↔ N/A
Bowman et al. (22) 2017 RCT 133 5 ± 5 UWSF ↔ ↔ N/A N/A N/A
























































































TABLE 1 | Continued
Therapy References Year Baseline characteristics Effect on SG function SG inflammation


























T cells ↔ B
cells ↔
N/A
Verstappen et al. (26) 2017 Open label 30 N/A N/A N/A N/A Ectopic GC ↓ N/A
Meiners et al. (27) 2014 Pilot RCT 15 0.92 (0.58-3) SWSF ↔
UWSF ↔
N/A N/A N/A N/A
van Nimwegan et al. (28) 2020 RCT 80 2 (1–4) SWSF ↔
UWSF ↔
↔ N/A N/A N/A
Baer et al. (29) 2020 RCT 187 5.0 SWSF ↔ ↔ N/A N/A N/A
Machado et al. (30) 2020 Open label 11 N/A ↑ N/A N/A N/A N/A
Prezalumab Mariette et al. (31) 2019 RCT 32 N/A N/A N/A N/A Tfh-like cells ↓
PCs ↔
N/A
Iscalimab Fisher et al. (32) 2020 RCT 10 N/A SWSF↑
UWSF↑
↓ N/A N/A N/A
Belimumab Mariette et al. (33) 2013 Open label 30 5.7 (5.6) UWSF ↔ ↔ ↔ Parotid swelling
↓
N/A
de Vita et al. (34) 2015 Open label 30 5.9 (5.7) UWSF ↔ ↔ ↔ N/A N/A
Tocilizumab Felten et al. (35) (abstract) 2020 RCT 110 N/A UWSF ↔ ↔ N/A N/A N/A
SG, salivary gland; ESSDAI, EULAR Sjögren’s Syndrome Disease Activity Index; SWSF, stimulated whole salivary flow; UWSF, unstimulated whole salivary flow; VAS, visual analogue scales; RCT, randomized controlled trial; LEL,
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involving multiple centres, showed significant improvement in
total ultrasound score after therapy compared to placebo (23).
Histologically, whilst SG inflammation measured by Chilsom
and Mason grading were not originally improved in the TEARs
study (19), glandular B-cell depletion in an open label cohort was
observed 12 weeks after therapy, however this was not sustained
in the TEARs cohort at 24 weeks (21). Combined, the effect
of RTX therapy in pSS patients suggest some reversibility and
restoration of SG inflammation and function.
EFFECT OF T-CELL CO-STIMULATION
BLOCKADE ON SALIVARY GLAND
FUNCTION AND INFLAMMATION
Whilst pSS is often described as a disease of B-cell pathology,
much of their activation is mediated by T-cell-dependent
mechanisms. Antigen-presenting cells (APCs) in pSS SGs activate
infiltrating naïve T-cells, to differentiate into CD4+ effector T-
cells, such as T-helper 1 (Th1) and T-follicular helper (Tfh)
cells to initiate an in situ adaptive immune response. This
crucial event is mediated by activating co-stimulatory molecules
expressed on APCs, namely CD80/86, CD40 and inducible T-cell
co-stimulator (ICOS)-ligand, which bind CD28, CD40-ligand
(CD40L) and ICOS, respectively, on T-cells. On the contrary,
co-inhibitory signals can also be mediated through CD80/86 by
interacting with cytotoxic T lymphocyte antigen-4 (CTLA-4) on
T-cells. After antigen presentation, co-stimulation is the second
signal required for T-cell activation, hence exploiting this signal
could regulate perpetuation of the adaptive immune response in
pSS (45).
Abatacept, a soluble fusion protein targeting CTLA-4 to
inhibit CD28-mediated T-cell activation, has been approved for
the treatment of RA (46) and initial studies in pSS offered
promising results. Modulation of SG inflammation in the first
study on abatacept was evidenced by a reduction in total
number of lymphocytic foci (24). Whilst this could be due
to reduced T-cell activation, the suppressive effect of Tregs
can be enhanced in response to CTLA-4 blockade to enforce
immunological control (47). Abatacept could impact T/B-cell co-
stimulation in ectopic GCs, depleting them in parotid glands
(25, 26) and attenuating Tfh-dependent B-cell hyperactivity.
Abatacept stabilized glandular function in a pilot study enrolling
15 pSS patients (based on both SWSF and USWF rates), while
also significantly improving systemic manifestations of disease
(ESSDAI p < 0.001) at 24 weeks (27). Furthermore, improving
ESSDAI coincided with reduced expression of T-cell activation
marker ICOS, on SG Tfh cells after abatacept treatment (26). This
event may be key in modulating pSS pathogenesis, since ICOS
is essential for sustaining Tfh cell numbers. Disappointingly,
2 recent abatacept RCTs including the ASAP-III trial failed to
meet their primary outcomes (a between-group difference in
ESSDAI score at 24 weeks for both studies) with no glandular
secretory improvements (28, 29). More frequent administration
of abatacept coupled with longitudinal assessments could prove
to be more efficacious however, as 24 monthly administrations
showed systemic and functional efficacy at the end of an
open label study (p = 0.013 median ESSDAI and salivary
flow difference) (30). It is extremely important that selected
primary outcomes in RCTs are sensitive to detecting change since
they can be pivotal in reporting trial results, as shown by the
retrospective analysis of the ASAP-III cohort, where use of a
composite endpoint which considers systemic, patient-reported,
functional and biological outcomes, termed CRESS (composite
of relevant endpoints for SS), favored abatacept therapy
over placebo (48).
In pSS, CD4+ T-cells display an activating state, including
the upregulation of CD40L and ICOS costimulatory molecules
to aid in B-cell activation, immunoglobulin class-switching and
formation of ectopic GCs (6). Interestingly, ICOS deficiency
leads to impaired CD4+ memory T-cell differentiation (49) and
reduced circulating numbers of naïve, switched- and memory
B-cells with pan-hypogammaglobulinemia (50), suggesting
interference of this pathway may impact pSS pathogenesis.
Prezalumab (MED15872/AMG557) a humanized IgG2 antibody
targeting ICOS-L, usually expressed on B-cells and dendritic
cells, was recently tested in a phase IIa study (NCT02334306).
Despite proof of mechanisms evidence observed at 99 days
follow-up, with SG biopsies displaying significantly fewer ICOS+
Tfh-like cells in the treatment arm compared to placebo (p =
0.008) and marked improvements in circulating B-cell activation
markers (IgA-, IgG- and IgM-RF), the study disappointingly
did not meet its primary endpoint (mean change in ESSDAI)
(31). Post-hoc analyses on glandular function from this study
is yet to be reported. To interrupt CD40-mediated T-cell-co-
stimulation, Iscalimab (CFZ533) a novel antagonistic, non-
depleting anti-CD40 mAb has been tested in pSS. Results
from the first proof-of-concept RCT (NCT02291029) showed
improvements in both stimulated and unstimulated salivary
flow rates (0.04 and 0.16 ml/min, respectively) 12 weeks after
treatment. Coupled with a reduction in patient-reported VAS
assessments (mean decrease of 8.14 points), results from this
study are promising as it is the first to show clinically meaningful
improvements compared to placebo (based on ESSDAI). As of
yet, ultrasonography assessment from this study are unreported,
hence the assessment of Iscalimab on SG morphology is
awaited (32).
EFFECT OF CYTOKINE BLOCKADE ON
SALIVARY GLAND FUNCTION AND
INFLAMMATION
In pSS, a dysregulated cytokine network impairs glandular
function and induces chronic inflammation systemically, making
them susceptible to therapeutic targeting (51). Several cytokine
families underlie the etiopathogenesis of pSS, including the
interferon (IFN) family, tumor necrosis factor (TNF) family
and IL-6, IL-2, IL-10, and IL-17 families (52). The type-I IFN
system is induced by environmental factors in autoimmune
epithelitis during early stages of disease to trigger recognition
of self-antigens through pattern recognition receptors, and as
such, a type-I IFN signature has been identified in pSS patients
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(53, 54). Binding of IFNs to their receptors activate the Janus-
kinase (JAK)-signal transducer and activator of transcription
(STAT) pathway, hence JAK/STAT pathway blockade could
provide therapeutic benefit (52). Tofacitinib, a JAK inhibitor
improved sicca symptoms in a group of patients with dry
eye disease (55) whilst the JAK1 inhibitor, filgotinib has
been shown to improve salivary flow in an animal model
of pSS (56) and has been successful in RA treatment (57).
Data describing the efficacy of JAK/STAT pathway blockade
in pSS are lacking, hence results from the most recent RCT
targeting this pathway with filogitinib are eagerly awaited
(NCT03100942) (58).
A beneficial knock-on effect of IFN blockade through JAK1
inhibition is the downregulation of B-cell activating factor
(BAFF) as observed in mice, since it is under the transcriptional
control of IRF1 and IRF2 (56). BAFF [also called B lymphocyte
stimulator (BLys)] belongs to the TNF family and as a critical
cytokine for B-cell maturation and differentiation produced by
haematopoietic and non-hematopoietic cells (59), its aberrant
expression has been observed in the sera of pSS patients (60,
61) and in infiltrating SG lymphocytes (62, 63). Belimumab, a
IgG1λ mAb neutralizing soluble BAFF has been approved for
the treatment of systemic lupus erythematosus (64, 65) and
is a promising treatment approach for pSS. In the proof-of-
concept Belimumab in Sjogren’s syndrome (BELISS) trial, a
dosage of 10 mg/kg at weeks 0, 2, 4 and monthly thereafter
for 6 months was evaluated and showed efficacy in 60% of
the anti-SSA/B+ cohort (33). Specifically, this described a
≥30% VAS reduction in at least 2 of the following: dryness,
fatigue, musculoskeletal pain, systemic activity assessed by a
clinician and/or >25% improvement in any B-cell activation
biomarkers. Despite significant reductions in parotid swelling
and ESSDAI from baseline, improvements in SG function were
not observed at 28 weeks (UWSF 0.6–0.7 mL/min, p = 0.27)
nor were there significant changes in focus score (1.9–1.7, p =
0.57) (33) with similar effects observed long-term at 52 weeks
(34). Post-hoc analysis showed belimumab restore circulating B-
cell subset frequencies (66) however larger, blinded studies on
belimumab are required for future trials focused on improving
glandular function.
Interestingly, BAFF has been implicated in resistance to RTX.
It emerged in-vivo that complete B-cell depletion could be
sustained in mice following anti-BAFF therapy (67), suggesting a
sequential, double therapeutic approach could be more effective
than lone monotherapy in pSS. This biological rationale lead to
the successful treatment of a pSS patient with MALT lymphoma
and refractory cryoglobulinaemic vasculitis. Following failed
belimumab monotherapy, the administration of RTX shortly
after resulted in persistent clinical and biological efficacy, such as
healing of skin ulcers, amelioration of circulating autoantibody
and normalization of serum BAFF. Remarkably, a 9-year follow-
up showed stable remission of lymphoma (68). Validation of the
safety and efficacy of this sequential therapy has been evaluated
in a multi-national pSS RCT (NCT02631538), which have now
completed recruitment but the results are yet to be published.
IL-6 has a role in mediating the polarization of Tfh cells
(69), B-cell activation and autoantibody production (70) and
in pSS is highly expressed in serum, saliva (71) and SGs (72).
Perturbing its action by tocilizumab (an anti-IL-6 receptor) has
been found to be effective in RA (73) and two cases of pSS [one
with refractory organizing pneumonia (74) and another with
neuromyelitis optica spectrum disorder (75)]. Findings from the
most recent RCT testing tocilizumab in a cohort of pSS patients
(NCT01782235) has failed to meet its primary endpoint with no
response observed at week 24. There was no effect on UWSF or
circulating immunoglobulins or complement, suggesting that IL-
6 may not be the main driver of B-cell hyperactivity in pSS (35).
Limiting the primary outcome to a 3-point reduction in ESSDAI,
however, lead to a high placebo effect, reinforcing the need to
validate this outcome measure for use in RCTs. Other reasons for
variability in the efficacy of cytokine-targeted biologics could be
due to the redundant targeting of single candidates, as it may not
restore all inflammation-induced damage, given the complexity
of pSS pathogenesis. Exploration of alternative combination
therapies could result in both clinical and biological efficacy
in pSS.
CONCLUSION
Based on our understanding of pSS pathogenesis and the
mechanisms involving B-cells, T-cell co-stimulation and
the complex network of cytokines, biologics have increased
the armamentarium used for the potential treatment of this
disease. Whilst this mini-review highlights promising results
from recent RCTs, controversial data have made it clear
that there is an urgent need to further our understanding
of biological therapy in this field. For example, the failure
to achieve direct and consistent clinical benefits may be
overcome by exploring combinatorial therapies, taking a
more holistic approach to pSS treatment. RCTs must also
be well-designed and apply realistic, achievable primary
outcome measures that are sensitive to change and consider
the subjective, heterogenic nature of the clinical manifestations
observed. Whilst ESSDAI assesses systemic disease activity,
there are limitations to its use as an endpoint in RCTs
(76, 77), hence progression is being made by the IMI2-
NECESSITY consortium (https://www.imi.europa.eu/projects-
results/project-factsheets/necessity) for the development of
a reliable and validated composite outcome measure to be
used in future pSS clinical trials. These changes, together
with increased understanding of pathogenetic pathways
could identify novel targets to be exploited by future
biological therapy.
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